NASDAQ
81.45USD
+0.63 (+0.78%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.9B
P/E
—
EPS
—
Beta
0.52
52W range
78.65-118.01
Day range
79.40–81.83
Open
80.69
Prev close
80.82
Volume
427.9K
Avg volume
305.6K
Dividend
0.90
IPO
2006-10-19
https://www.globenewswire.com/news-release/2026/07/14/3327365/10507/en/LeMaitre-Will-Announce-Second-Quarter-2026-Earnings-Results-on-August-4-2026.html · 7/14/2026+0.00
https://www.zacks.com/stock/news/2917361/3-reasons-growth-investors-will-love-lemaitre-lmat?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_11_growth-2917361 · 5/7/2026+1.00
https://www.globenewswire.com/news-release/2026/04/07/3269567/10507/en/LeMaitre-to-Present-at-the-25th-Annual-Needham-Virtual-Healthcare-Conference.html · 4/7/2026+0.80
https://www.defenseworld.net/2026/03/07/lemaitre-vascular-inc-nasdaqlmat-receives-105-80-average-target-price-from-analysts.html · 3/7/2026+0.10
https://www.zacks.com/stock/news/2877545/lemaitre-vascular-lmat-s-technical-outlook-is-bright-after-key-golden-cross?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|golden_crossover-2877545 · 3/2/2026+0.90
https://www.globenewswire.com/news-release/2026/02/11/3236414/10507/en/LeMaitre-Will-Announce-Fourth-Quarter-2025-Earnings-Results-February-25-2026.html · 2/11/2026+0.00
https://www.defenseworld.net/2026/02/07/lemaitre-vascular-inc-nasdaqlmat-given-consensus-rating-of-moderate-buy-by-brokerages.html · 2/7/2026+0.40
https://www.defenseworld.net/2025/12/13/lemaitre-vascular-inc-lmat-shares-sold-by-awm-investment-company-inc.html · 12/13/2025-0.20
https://www.zacks.com/stock/news/2774363/phg-or-lmat-which-is-the-better-value-stock-right-now?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_3-2774363 · 10/22/2025-0.40
https://seekingalpha.com/article/4823150-lemaitre-vascular-stock-investment-debate-remains-in-place-reiterate-buy · 9/16/2025+1.00
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works